Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines

Restricted access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.

  • 1

    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:1029.

  • 2

    Andriole GL, Crawford ED, Grubb RL III. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125132.

    • Search Google Scholar
    • Export Citation
  • 3

    Hugosson J, Carlsson S, Aus G. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725732.

    • Search Google Scholar
    • Export Citation
  • 4

    Sandblom G, Varenhorst E, Rosell J. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011;342:d1539.

  • 5

    Schroder FH, Hugosson J, Roobol MJ. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981990.

  • 6

    D’Amico AV, Whittington R, Malkowicz SB. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969974.

    • Search Google Scholar
    • Export Citation
  • 7

    Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000;48:111117.

    • Search Google Scholar
    • Export Citation
  • 8

    Masson S, Persad R, Bahl A. HDR Brachytherapy in the management of high-risk prostate cancer. Adv Urol 2012;2012:980841.

  • 9

    Al-Salihi O, Mitra A, Payne H. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy. Prostate Cancer Prostatic Dis 2006;9:370373.

    • Search Google Scholar
    • Export Citation
  • 10

    Fang FM, Wang YM, Wang CJ. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol 2008;38:474479.

    • Search Google Scholar
    • Export Citation
  • 11

    Pieters BR, van de Kamer JB, van Herten YR. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 2008;88:4652.

    • Search Google Scholar
    • Export Citation
  • 12

    Soumarova R, Homola L, Perkova H, Stursa M. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: comparison of acute toxicity. Tumori 2007;93:3744.

    • Search Google Scholar
    • Export Citation
  • 13

    Sathya JR, Davis IR, Julian JA. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23:11921199.

    • Search Google Scholar
    • Export Citation
  • 14

    Hoskin PJ, Motohashi K, Bownes P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007;84:114120.

    • Search Google Scholar
    • Export Citation
  • 15

    Hoskin PJ, Rojas AM, Bownes PJ. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012;103:217222.

    • Search Google Scholar
    • Export Citation
  • 16

    Shen X, Keith SW, Mishra MV. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 2012;83:11541159.

    • Search Google Scholar
    • Export Citation
  • 17

    Bittner N, Merrick GS, Butler WM. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy 2012;11:250255.

    • Search Google Scholar
    • Export Citation
  • 18

    Martinez-Monge R, Moreno M, Ciervide R. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys 2012;82:e469476.

    • Search Google Scholar
    • Export Citation
  • 19

    D’Amico AV, Moran BJ, Braccioforte MH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009;27:39233928.

    • Search Google Scholar
    • Export Citation
  • 20

    Demanes DJ, Brandt D, Schour L, Hill DR. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol 2009;32:342347.

    • Search Google Scholar
    • Export Citation
  • 21

    Dattoli M, Wallner K, True L. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. J Oncol 2010;2010:471375.

    • Search Google Scholar
    • Export Citation
  • 22

    Konaka H, Egawa S, Saito S. Tri-modality therapy with I-125 brachytherapy, external beam radiation therapy, and shortor long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 2012;12:110.

    • Search Google Scholar
    • Export Citation
  • 23

    Holzbeierlein J, Lal P, LaTulippe E. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217227.

    • Search Google Scholar
    • Export Citation
  • 24

    Mohler JL, Gregory CW, Ford OH III. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440448.

  • 25

    Attard G, Reid AH, A’Hern R. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:37423748.

    • Search Google Scholar
    • Export Citation
  • 26

    Scher HI, Fizazi K, Saad F. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study [abstract]. J Clin Oncol 2012;30(Suppl):Abstract LBA1.

    • Search Google Scholar
    • Export Citation
  • 27

    de Bono JS, Logothetis CJ, Molina A. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:19952005.

  • 28

    Ryan CJ, Shah S, Efstathiou E. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011;17:48544861.

    • Search Google Scholar
    • Export Citation
  • 29

    Ryan CJ, Smith MR, Fong L. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:14811488.

    • Search Google Scholar
    • Export Citation
  • 30

    National Institutes of Health. Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00887198. Accessed April 16, 2012.

    • Search Google Scholar
    • Export Citation
  • 31

    de Bono JS, Oudard S, Ozguroglu M. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:11471154.

    • Search Google Scholar
    • Export Citation
  • 32

    Kantoff PW, Higano CS, Shore ND. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411422.

  • 33

    National Institutes of Health. Sequencing of sipuleucel-T and ADT in men with non-metastatic prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01431391. Accessed April 16, 2012.

    • Search Google Scholar
    • Export Citation
  • 34

    National Institutes of Health. Concurrent versus sequential treatment with sipuleucel-T and abiraterone in men with metastatic castrate resistant prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01487863. Accessed April 16, 2012.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 853 570 21
PDF Downloads 136 86 4
EPUB Downloads 0 0 0